載入中
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
一般交易時段
US$18.1789
+US$0.5489 · +3.11%
盤中時間採用ET。市場資料可能有所延遲。
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
日內區間
目前US$18.1789
52週區間
目前US$18.1789
盤中時間採用ET。市場資料可能有所延遲。
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
日內區間
目前US$18.1789
52週區間
目前US$18.1789
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 營收 | 1億 USD | 6512.4萬 USD | 1199.5萬 USD | 17.9萬 USD |
| 銷貨成本 | 4471.4萬 USD | 2923.6萬 USD | 568.7萬 USD | — |
| 毛利 | 5553.7萬 USD | 3588.8萬 USD | 630.8萬 USD | 17.9萬 USD |
| 研究與開發 | 3478.9萬 USD | 2618.4萬 USD | 1794.3萬 USD | 3142.8萬 USD |
| 銷售、一般及管理費用 | 9242.9萬 USD | 5495.5萬 USD | 2421.5萬 USD | 3349.5萬 USD |
| 營業費用 | 1.27億 USD | 8113.9萬 USD | 4215.8萬 USD | 6602.3萬 USD |
| 利息收入 | 1093.2萬 USD | 390.9萬 USD | 177.7萬 USD | 19.6萬 USD |
| 利息支出 | — | — | — | 1.4萬 USD |
| 折舊和攤銷 | 287.5萬 USD | 228.3萬 USD | 209.1萬 USD | 208.7萬 USD |
| 營業利益 | −7168.1萬 USD | −4525.1萬 USD | −3585萬 USD | −6584.4萬 USD |
| 淨利 | −7320萬 USD | −5475.6萬 USD | −4409.9萬 USD | −6475.1萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$24.75
上漲空間 36.15%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2538.65萬0.00%2.3兆 USD0.03%US$382.11+0.04%
iShares Russell 2000 ETFIWM1876.09萬0.02%787.4億 USD0.19%US$278.76-0.06%
Vanguard Extended Market ETFVXF937.84萬0.01%954億 USD0.05%US$234.61-0.17%
iShares Russell 2000 Value ETFIWN673.79萬0.05%137.49億 USD0.24%US$211.1+0.11%
T. Rowe Price Small-Mid Cap ETFTMSL527.74萬0.17%30.87億 USD0.55%US$41.115-0.16%
Vanguard Russell 2000 ETFVTWO466.66萬0.03%180億 USD0.06%US$112.63-0.03%
Schwab U.S. Small-Cap ETFSCHA419.78萬0.02%218.24億 USD0.03%US$32.765-0.08%
iShares U.S. Medical Devices ETFIHI392.73萬0.11%35.74億 USD0.37%US$52.08+0.66%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNT. Rowe Price Small-Mid Cap ETFTMSLVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Medical Devices ETFIHIAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
